IperionX Shares Remain Stuck in the Red as Operational Milestones Stack Up

Stock down 31% YTD and 55% below January high, despite strong feasibility study, analyst upgrades, and operational progress. Revenue still two years away, but management sees positive EBITDA by 2026.

A definitive feasibility study pegging the after-tax net present value at $813 million, an internal rate of return of 39%, and a payback period of just 3.6 years — none of it has been enough to pull IperionX out of its slump. The stock inched up 2.53% to €2.27 on Monday, a modest gain that comes after a month-long slide of 33%. The disconnect between project economics and market sentiment has rarely been starker.

Two analysts recently raised their price targets on the Australian titanium developer. Roth Capital lifted its target from $71 to $75, maintaining a buy rating. BTIG went further, hiking from $40 to $55 and also keeping a buy recommendation. The catalyst was the release of the definitive feasibility study for the company’s flagship Titan project, which envisions a single US deposit yielding titanium, zircon, and rare earths over a 14-year mine plan. Despite the bullish calls, five of six covering analysts recommend buying while one advises selling.

The operational picture is also brightening. IperionX’s titanium campus in Virginia exited the test phase in June and is now operating around the clock. The continuous production of titanium powder marks a significant step toward commercial scale. Yet customer revenue is not expected until the second half of calendar 2026, after qualification programs are completed and new sintering ovens expand manufacturing capacity.

In Tennessee, the company has moved to shore up its raw material base. It acquired mineral rights, inventory, mining equipment, and rail infrastructure from Covia Solutions LLC in Camden for $3 million. The site sits directly adjacent to the Titan project within the Big Sandy Critical Minerals Province. The deal also brings reclamation obligations, including regrading, revegetation, and stabilization. The acquisition consolidates IperionX’s resource position and provides additional supply options for the Titan project.

The market, however, remains fixated on the revenue vacuum. The stock has lost about 31% since the start of the year and sits more than 55% below its January high of €5.09. The 200-day moving average of €3.46 is a distant 34% above the current price. The relative strength index has fallen to around 31 — hovering just above the classic oversold threshold of 30 — driven in part by tax-loss selling ahead of the Australian fiscal year-end on June 30. With that seasonal pressure now behind it, some short-term buyers have begun to nibble.

Management expects a positive EBITDA contribution by the end of 2026, and the company projects a cash balance of $36 million to $40 million by June 30, 2026. The feasibility study that analysts are citing as the basis for their target raises also calculates an overall project value of roughly $1.14 billion — a figure that far exceeds the current market capitalisation.

An upcoming investor meeting with B. Riley could provide a fresh catalyst for attention. But the real test will come later this year, when production costs at the Virginia plant become clearer and the GenX technology platform is expected to deliver concrete commercial proof. Until then, IperionX’s share price remains caught between operational progress and the cold reality of a still-distant revenue stream.